Centaurus Financial, Inc. Biomarin Pharmaceutical Inc Transaction History

Centaurus Financial, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 17, 2023	SELL	$87.74 - $117.27 $8,774 - $11,727	-100 Reduced 8.3%	1,105 $107,000
Q4 2022 Feb 10, 2023	SELL	$80.93 - $108.63 $9,873 - $13,252	-122 Reduced 9.19%	1,205 $124,000
Q3 2022 Dec 05, 2022	BUY	$82.16 - $96.94 $109,026 - $128,639	1,327 New	1,327 $112,000
Q1 2022 May 13, 2022	SELL	$74.28 - $92.69 $89,507 - $111,691	-1,205 Closed	0 $0
Q4 2021 Feb 01, 2022	BUY	$71.72 - $91.47 $86,422 - $110,221	1,205 New	1,205 $106,000
Q1 2020 Apr 21, 2020	SELL	$71.37 - $96.85 $102,059 - $138,495	-1,430 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$64.27 - $86.37 $91,906 - $123,509	1,430 New	1,430 $121,000
Q3 2019 Nov 12, 2019	SELL	$67.4 - $85.11 $103,122 - $130,218	-1,530 Closed	0 $0
Q2 2019 Aug 15, 2019	BUY	$80.35 - $93.9 $122,935 - $143,667	1,530 New	1,530 $131,000
Q3 2018 Nov 05, 2018	SELL	$93.92 - $105.72 $59,263 - $66,709	-631 Closed	0 $0
Q2 2018 Aug 15, 2018	BUY	$76.01 - $99.03 $47,962 - $62,487	631 New	631 $59,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Centaurus Financial, Inc., based on Form 13F filings with the SEC.

Stay updated on Centaurus Financial, Inc. with notifications on news.